Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

AIMS/HYPOTHESIS: Type 1 diabetes results from T cell mediated destruction of beta cells. We conducted a trial of antithymocyte globulin (ATG) in new-onset type 1 diabetes (the Study of Thymoglobulin to ARrest T1D [START] trial). Our goal was to evaluate the longer-term safety and efficacy of ATG in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gitelman, Stephen E., Gottlieb, Peter A., Felner, Eric I., Willi, Steven M., Fisher, Lynda K., Moran, Antoinette, Gottschalk, Michael, Moore, Wayne V., Pinckney, Ashley, Keyes-Elstein, Lynette, Harris, Kristina M., Kanaparthi, Sai, Phippard, Deborah, Ding, Linna, Bluestone, Jeffrey A., Ehlers, Mario R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869699/
https://www.ncbi.nlm.nih.gov/pubmed/27053235
http://dx.doi.org/10.1007/s00125-016-3917-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869699/
https://www.ncbi.nlm.nih.gov/pubmed/27053235
http://dx.doi.org/10.1007/s00125-016-3917-4

Ejemplares similares